Company / EPS (Diluted)
RIGEL PHARMACEUTICALS INC EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.44
FY2025
5-year range
-$3.44 / -$0.11
FY2021-FY2025
Trend
+58.1%
vs FY2024
Sector context
#99 of 204
Health Care
What the data says
At $-1.44, RIGEL PHARMACEUTICALS INC's eps (diluted) ranks #99 of 204 in the Health Care sector. Declined from $-0.11 to $-1.44 over the past 2 years.
Based on SEC 10-K filings.
-1.44 in FY2025.
Declined from $-0.11 to $-1.44 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#99 of 204 in Health CareTop 49% of 204This company -$1.44 Sector average -$0.98
▼
-47.0% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 58.1% year-over-year.
- Ranks #99 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.44 | +58.1% |
| FY2024 | -$3.44 | -3027.3% |
| FY2023 | -$0.11 | +38.9% |
| FY2022 | -$0.18 | +55.0% |
| FY2021 | -$0.40 | +9.1% |
| FY2020 | -$0.44 | +29.0% |
| FY2019 | -$0.62 | +15.1% |
| FY2018 | -$0.73 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026